A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors

F. E. Stuurman, Martijn P. Lolkema, Alwin D. R. Huitema, P. M. M. B. Soetekouw, Hilde Rosing, L. Rolfe, P. Kaur, Jos H. Beijnen, H. van Tinteren, E.E. Voest, Jan H. M. Schellens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)878-883
JournalJournal of Clinical Pharmacology
Issue number8
Publication statusPublished - Aug 2013


  • gemcitabine
  • CO-101
  • CP-4126
  • bioequivalence
  • QT
  • QTc intervals
  • dFdC
  • dFdU
  • phase 1
  • lipid
  • phospholipids
  • cancer
  • formulation
  • infusion

Cite this